In 2019, ramucirumab, a monoclonal antibody targeting the VEGF receptor 2, was approved for patients with tumor progression under sorafenib and elevated alpha-fetoprotein (AFP ≥ 400 ng/mL) [9]. The gene discussed is AFP; the disease is neoplasm.